TGRX-1942
/ Shenzhen TargetRx
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
February 24, 2025
TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies
(clinicaltrials.gov)
- P1 | N=90 | Recruiting | Sponsor: Shenzhen TargetRx, Inc. | Not yet recruiting ➔ Recruiting | Trial completion date: Aug 2027 ➔ Jun 2027
Enrollment open • Trial completion date • Hematological Disorders • Hematological Malignancies • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor
July 03, 2024
TGRX-1942 Chinese Phase I for Advanced Solid Tumor and/or Relapsed/Refractory Hematologic Malignancies
(clinicaltrials.gov)
- P1 | N=90 | Not yet recruiting | Sponsor: Shenzhen TargetRx, Inc.
Metastases • New P1 trial • Hematological Disorders • Hematological Malignancies • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor
1 to 2
Of
2
Go to page
1